Een opmerking die opvalt is dat prostaatkankerpatiënten die PC-Spes hebben gebruikt of gebruiken niet reageren op de naltrexone in tegenstelling tot andere prostaatkankerpatiënten die er wel op reageren. Maar zo beschrijft Dr. Bihari het.
Since February 1999, Dr. Bihari has begun treatment of 242 cancer patients with LDN (see chart below). Since many of these patients, particularly those seen before October 2000, were seen only once in consultation with medical follow-up by their oncologists, he is missing up-to-date follow-up data on 96 patients.
As of March 2001, of the remaining 146 patients, 44 have died, all but 4 of cancer-related causes. Most of these deaths have occurred in the first 8 to 12 weeks on LDN. For the most part, these were patients who were quite ill when first seen, and had exhausted all other treatment possibilities. Of the remaining 102 patients, 44 have been on LDN for six months or longer. Of these, 21 have shown significant movement toward remission, identified for this purpose as a reduction of at least 75% in tumor mass and tumor-related symptoms. The other 23 patients have stabilized and/or are moving toward remission but do not yet meet the 75% reduction criterion.
Of the 58 patients not on LDN for six months as yet, 9 continue to show disease progression and 49 have stabilized with no disease progression and/or reduction of less than 75% in tumor bulk.
Among the 21 who have shown significant movement toward remission, 6 had never received chemotherapy. Another 9 stopped chemotherapy during the first 3 to 4 months on LDN, and the remaining 6 are still receiving chemotherapy. The apparent remissions include:
2 children with neuroblastoma
3 patients with non-Hodgkin's lymphoma
2 with Hodgkin's disease
2 with pancreatic cancer
3 with multiple myeloma
1 with carcinoid
1 with breast cancer metastatic to bone
4 with ovarian cancer
1 with small cell cancer of the lung
2 with prostate cancer (no prior hormone-blocker therapy)
(Although recently-diagnosed prostate cancer patients who have not received other therapies appear to do well on LDN, patients with prostate cancer who have already been treated with hormone-related therapies, including testosterone-blocking drugs and PC-Spes, have not responded to LDN.)
An overview of these results must assume on basic statistical principle that the patients with no follow-up contact have not done as well as those who have maintained continual medical contact with Dr. Bihari. Measured in terms of disease stabilization and/or movement toward remission, and assuming that patients in continual follow-up are twice as likely to have had a good outcome thus far, it appears that one-quarter to one-third of all cancer patients who Dr. Bihari has started on LDN have done well.
Taking into account the relatively large number of patients who were in advanced stages of disease when first seen by Dr. Bihari, it appears that somewhere between 30% and 50% of patients with cancer may benefit from LDN. It will clearly require extensive study of LDN in prospective, controlled clinical trials to determine which cancers respond best and which other therapies are complementary or synergistic with LDN
- Naltrexone blijkt een prima middel bij auto-immuunziektes. Zie hier laatste studieresultaten bij o.a. ziekte van Crohn, MS - Multiple Sclerose en uitleg wat LDN - Low Dose Naltrexone precies is.
- Het werkingsmechanisme van Naltrexone
- Onderzoeksgeschiedenis van Naltrexone
- Beschrijving van 242 patienten die naltrexone kregen als aanvullende behandeling.
- Voorbeelden van patiënten die Naltrexone gebruiken.
- LDN - Low Dose Naltrexone is een niet toxisch middel dat voor enkele toepassingen goedgekeurd is door de FDA